Therapeutic drug monitoring turned a difficult combination into a documented treatment in a patient with carbapenem resistant Klebsiella pneumoniae. The organism produced an NDM type metallo beta lactamase and a second serine beta lactamase, and it caused both a bloodstream infection and an intra abdominal infection after severe acute pancreatitis. Aztreonam avibactam was chosen on susceptibility results, given at a fixed regimen, and checked with measured trough concentrations on four treatment days. The levels sat well above the organism's minimum inhibitory concentration, and the patient improved. Rifampicin and rifabutin induce drug metabolizing enzymes and transporters, so the exposure question at the center of this case is one the rifamycin family often raises.
Why therapeutic drug monitoring mattered here
Critically ill patients do not handle drugs the way healthy volunteers do. Fluid shifts, organ failure, kidney replacement, and low albumin all alter volume of distribution and clearance. A standard dose may land far below or far above the intended exposure. When the organism resists most available agents, guessing is a weak plan.
This patient had severe acute pancreatitis with multiple organ dysfunction. Blood cultures and peripancreatic drainage fluid both grew the same carbapenem resistant organism. Phenotypic testing showed that aztreonam avibactam was active in vitro and ceftazidime avibactam was not. Sequencing later identified why: a blaNDM like gene nearly identical to blaNDM 1, plus an SHV2 like class A beta lactamase.
The drug choice was sound on paper. What remained was whether the dose would produce enough exposure at the site of infection. Measuring concentrations answered that with data instead of assumption.
What the case involved
The patient was a 40 year old adult admitted with respiratory and circulatory failure and multiple organ dysfunction. Admission laboratory work showed leukocytosis, with a white cell count of 18.45 times ten to the ninth per liter and 92.0 percent neutrophils. Inflammatory markers were high. Amylase was 875 units per liter on admission and 2613 at another point. Imaging showed peripancreatic collections but no gallstones or biliary dilation.
Continuous renal replacement therapy was used early and stopped on inpatient day 5. Recurrent fever followed, and on day 22 both blood and drainage fluid yielded carbapenem resistant Klebsiella pneumoniae. Aztreonam avibactam started on day 27, after susceptibility results were available.
Inpatient day | Event | Relevance |
Day 1 | Admission with circulatory and respiratory failure | Baseline severity, lactate 2.20 millimoles per liter |
Day 5 | Continuous renal replacement therapy stopped | Before later TDM measurements |
Day 22 | Blood and drainage fluid grew carbapenem resistant K. pneumoniae | Pathogen identified from two sites |
Day 27 | Aztreonam avibactam started | 2 g aztreonam plus 0.5 g avibactam every 6 hours |
Days 27, 30, 33, 40 | Trough concentrations measured | Treatment days 1, 4, 7, 14 |
Days 34 and 39 | Blood cultures negative | Microbiological response |
Day 43 | Safety laboratory assessment | Treatment day 17 |
Day 45 | Discharge | Sustained clinical improvement |
Susceptibility and resistance mechanism
Phenotypic testing gave a clean split. Aztreonam avibactam produced a 32 millimeter inhibition zone with a minimum inhibitory concentration below 0.064 milligrams per liter, read as susceptible. Ceftazidime avibactam was inactive at a minimum inhibitory concentration above 16 milligrams per liter. The mechanism fits. Aztreonam resists metallo beta lactamase hydrolysis, while avibactam inhibits the serine beta lactamases often co produced.
Sequencing confirmed the phenotype. The isolate carried a blaNDM like carbapenemase gene with 99.3 percent identity to blaNDM 1 and an SHV2 like class A beta lactamase gene. Features linked to capsule formation, lipopolysaccharide biosynthesis, and the PmrAB regulatory system were found separately. The genomic result did not change therapy. It explained why the phenotypic test favored one combination over the other.
The therapeutic drug monitoring results
Aztreonam avibactam ran for 14 inpatient days, from day 27 through day 40, at 2 g aztreonam plus 0.5 g avibactam intravenously every 6 hours. The avibactam was not available through the inpatient pharmacy and was procured by the family from an external source. Trough plasma concentrations were measured by liquid chromatography tandem mass spectrometry on treatment days 1, 4, 7, and 14.
Treatment day | Inpatient day | Aztreonam trough, micrograms per milliliter | Avibactam trough, micrograms per milliliter |
Day 1 | Day 27 | 23 | 5.17 |
Day 4 | Day 30 | 20.29 | 2.45 |
Day 7 | Day 33 | 58.1 | 17.44 |
Day 14 | Day 40 | 61.57 | 18.37 |
Every trough sat substantially above the isolate's aztreonam avibactam minimum inhibitory concentration of less than 0.064 milligrams per liter. The report is careful about the limits of that comparison. Total concentrations were measured, not unbound ones, and only the free fraction is microbiologically active. Sampling also occurred at selected clinical points rather than in a formal pharmacokinetic study.
Safety parameters were checked on treatment day 17, or inpatient day 43. Platelet count was 243 times ten to the ninth per liter, alanine aminotransferase 25 units per liter, aspartate aminotransferase 22, total bilirubin 7.5 micromoles per liter, and creatinine 56 micromoles per liter. Earlier values on days 4 and 7 were also stable. No clinically significant hepatic, renal, or hematologic abnormality appeared during therapy.
A counterintuitive point about exposure
The lowest aztreonam trough was 20.29 micrograms per milliliter and the highest 61.57, a three fold spread. Avibactam troughs ranged from 2.45 to 18.37, more than seven fold. All of these values were described as adequate, because the organism's minimum inhibitory concentration was extremely low.
That contrast carries the practical lesson. Adequacy is a relationship between exposure and organism, not a stand alone number. A concentration that looks modest against one pathogen can be far above the threshold for another. A drug can also reach a high measured level and still fail if the organism's minimum inhibitory concentration is higher. This case makes the point visible because the organism sat at the susceptible extreme.
Where rifamycin interactions belong in this story
Therapeutic drug monitoring is usually invoked when exposure is unpredictable. Rifampicin is the classic case. It induces CYP3A4 and P glycoprotein and can reduce exposure to many co administered medicines, sometimes sharply. Rifabutin is a weaker inducer and is often selected when that property matters. Rifaximin acts mainly in the gut, while rifamycin sodium and rifamycin S occupy different formulation and intermediate roles.
None of these agents was given here. The relevance is methodological. When a rifamycin is in a regimen, the assumption that a fixed dose yields a fixed exposure is especially weak. The reasoning that led the team to measure aztreonam and avibactam troughs applies with more force to a combination containing a strong enzyme inducer. For a producer of rifamycin active ingredients, the case shows why exposure data and interaction labeling belong in the product story.
Practical implications
Several decisions transfer from this case.
- Choose the combination from the resistance mechanism, then confirm it phenotypically.
- Measure exposure when physiology is unstable, not only when toxicity appears.
- Read concentrations against the organism's minimum inhibitory concentration, not a generic target.
- State whether total or unbound drug was measured, since only free drug is active.
- Separate source control from antimicrobial effect when attributing improvement.
- Keep enzyme induction in view. Rifampicin containing regimens often lower exposure unexpectedly.
Limitations
One case report cannot be generalized. The patient improved after both drainage and antimicrobial therapy, and the report declines to credit the drug alone. TDM used selected time points rather than a formal pharmacokinetic protocol. Unbound concentrations were not measured, so the comparison with the minimum inhibitory concentration used total drug. Avibactam came from an external source, which leaves supply consistency unaddressed. Rifamycins were not given, so that discussion is context rather than a finding.
Bottom line
Therapeutic drug monitoring confirmed that a fixed aztreonam avibactam regimen produced troughs far above a highly susceptible organism's minimum inhibitory concentration in a critically ill patient, with stable safety parameters and improvement after source control. The case shows how exposure measurement turns an assumption into a documented fact. It also shows why the question matters in rifamycin containing therapy, where enzyme induction can pull exposure the other way.
FAQ
What is therapeutic drug monitoring?
It is the measurement of drug concentrations in blood at defined times to check that a dose produces the intended exposure. It is most useful when the relationship between dose and concentration is unpredictable, as in critical illness or with drugs that interact strongly. In this case trough concentrations of aztreonam and avibactam were measured on four treatment days by liquid chromatography tandem mass spectrometry. The results were then compared with the organism's minimum inhibitory concentration.
Why did this patient need it?
The patient had severe acute pancreatitis with multiple organ dysfunction and had received continuous renal replacement therapy. Those conditions change distribution and clearance, so a standard dose may not give a standard exposure. The infecting organism was resistant to carbapenems and most other agents. With few alternatives, confirming that the chosen combination actually reached adequate levels was a reasonable step rather than a luxury.
What organism was involved?
Blood and peripancreatic drainage fluid both grew carbapenem resistant Klebsiella pneumoniae. Phenotypic testing showed activity of aztreonam avibactam but not ceftazidime avibactam. Whole genome sequencing found a blaNDM like carbapenemase gene with 99.3 percent identity to blaNDM 1 and an SHV2 like serine beta lactamase gene. That combination explains why aztreonam, which resists metallo beta lactamase hydrolysis, worked alongside avibactam, which inhibits the co produced serine enzyme.
What were the measured trough concentrations?
Aztreonam troughs were 23, 20.29, 58.1, and 61.57 micrograms per milliliter on treatment days 1, 4, 7, and 14. Avibactam troughs were 5.17, 2.45, 17.44, and 18.37 micrograms per milliliter on the same days. All were well above the organism's aztreonam avibactam minimum inhibitory concentration of less than 0.064 milligrams per liter. The authors note that these were total, not unbound, concentrations.
Did the drug alone cure the patient?
The report does not claim that. CT guided drainage on inpatient day 22 provided source control for the infected peripancreatic collection, and targeted therapy started on day 27. Blood cultures on days 34 and 39 were negative and inflammatory markers fell. Both interventions preceded the improvement, so the authors describe a combined management strategy rather than crediting the antimicrobial alone.
How does rifampicin relate to a case that did not use it?
Through the exposure question. Rifampicin induces CYP3A4 and P glycoprotein and can lower the concentration of many co administered drugs. Rifabutin is a weaker inducer. The reasoning that led to measuring aztreonam and avibactam levels here applies strongly to any regimen containing a rifamycin, because a fixed dose is less likely to produce a fixed exposure. The connection is methodological, not a report of rifamycin use in this patient.
Were there safety problems?
No clinically significant hepatic, renal, or hematologic abnormality was observed. On treatment day 17, platelet count was 243 times ten to the ninth per liter, alanine aminotransferase 25 units per liter, aspartate aminotransferase 22, total bilirubin 7.5 micromoles per liter, and creatinine 56 micromoles per liter. Values measured earlier stayed in stable ranges as well.
What does a minimum inhibitory concentration below 0.064 mean?
It means the organism was inhibited by a very low concentration of the drug in vitro. The laboratory reported a value below the lowest tested level rather than an exact number. For comparison, the measured patient troughs were in the tens of micrograms per milliliter for aztreonam and several to nearly twenty for avibactam. That gap is why the report calls the exposure adequate, while still noting that unbound drug was not measured.
Can one case change clinical practice?
No. A single patient report generates a hypothesis and a practical illustration, not a guideline. It shows that measuring exposure was feasible and that the chosen regimen reached high levels with stable safety parameters in this person. Broader use would require more patients, formal pharmacokinetic sampling, and outcome comparisons. The authors present it as a documented case rather than a recommendation.
What should a pharmaceutical scientist take from it?
The case is a clean example of exposure as a relationship rather than a number. A trough in the tens of micrograms per milliliter would be unremarkable or inadequate for some organisms and far above target here. That habit of reading concentration against susceptibility applies to formulation and interaction work as well. With rifamycins, where induction can pull exposure down, the same discipline is even more important.